Lessons learned from long-term multiple sclerosis treatment trials

Multiple Sclerosis

Volumn 16, Issue 9, 2010, Pages 1028-1030

  Marriott, James J ^a   O'Connor, Paul W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NOTE; PROGNOSIS; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956331767     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510371410     Document Type: Note

References (22)

1. Ford C., Goodman AD, Johnson K., et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010 ; 16: 342-350.
2. Fisher E., Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002 ; 59: 1412-1420.
3. Bermel RA, Weinstock-Guttman B., Bourdette D., Foulds P., You X. and Rudick RA Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler, OnlineFirst DOI: 10.1177/i352458509360549.
4. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006 ; 67: 944-953.
5. Reder T., Ebers GC, Traboulsee A., et al. Cross-Sectional Study assessing long-term safety of interferon-Beta-1b for relapsing-remitting MS. Neurology 2010 ; 74 ; 1877-1885.
6. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 ; 50: 701-708.
7. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years. Mult Scler 2000 ; 6: 255-266.
8. Johnson KP, Ford CC, Lisak RP and Wolinsky JS Glatiramer acetate (Copaxone): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005 ; 111: 42-47.
9. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifroni G. and Wolinsky JS A prospective open-label study of glatiramer acetate: over a decade of continuous use in MS patients. Mult Scler 2006 ; 12: 309-320.
10. Ebers GC, Heigenhauser L., Daumer M., Lederer C. and Noseworthy JH Disability as an outcome in MS clinical trials. Neurology 2008 ; 71: 624-631.
11. Maguire MJ, Hemming K., Hutton JL and Marson AG Reporting and analysis of open-label extension studies of anti-epileptic drugs. Epilepsy Res 2008 ; 81: 24-29.
12. Coles A. Can the course of multiple sclerosis be modified? Pract Neurol 2005 ; 5: 278-287.
13. Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon-b-treated relapsing multiple sclerosis. Ann Neurol 2007 ; 61: 300-306.
14. Brown MG, Kirby S., Skedgel C., et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007 ; 69: 1498-1507.
15. Trojano M., Pellegrini F., Paolicelli D., et al. Real-life impact of early interferon 2 therapy in relapsing multiple sclerosis. Ann Neurol 2009 ; 66: 513-520.
16. Rudick RA and Cutter G. Interferon-2 for multiple sclerosis: long-term benefits? Ann Neurol 2007 ; 61: 283-285.
17. Heesen C., Gbadamosi J., Schoser BG, et al. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate - a case report. Eur J Neurol 2001 ; 8: 199.
18. Madray MM, Greene Jr JF and Butler DF Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol 2008 ; 65: 1378-1379.
19. Hashimoto S., Ball NJ and Tremlett H. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. Mult Scler 2009 ; 15: 521-522.
20. Day RO and Williams KM Open-label extension studies. Do they provide meaningful information on the safety of new drugs? Drug Saf 2007 ; 30: 93-105.
21. Taylor GJ and Wainwright P. Open label extension studies: research or marketing? Br Med J 2005 ; 331: 572-574.
22. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. Neurology 1995 ; 45: 1268-1276.